Published in Asia Pac Allergy on October 29, 2014
In the memory of Professor Felicidad Cua-Lim. Asia Pac Allergy (2014) 0.75
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet (2014) 4.36
ICON: food allergy. J Allergy Clin Immunol (2012) 2.65
The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy (2007) 1.91
Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol (2011) 1.57
Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children. Allergy (2011) 1.14
A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol (2013) 1.11
Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy (2006) 1.04
The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy (2009) 1.00
Oral peanut challenge identifies an allergy but the peanut allergen threshold sensitivity is not reproducible. PLoS One (2013) 0.99
CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy (2009) 0.99
Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep (2013) 0.98
Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma. Clin Exp Allergy (2011) 0.90
Effects of omalizumab in patients with food allergy. Allergy Asthma Proc (2010) 0.88
Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol Pract (2012) 0.83